Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 175

1.

Prospective, randomized, controlled, and open study in primarily inoperable, stage III non-small cell lung cancer (NSCLC) patients given sequential radiochemotherapy with or without epoetin alfa.

Debus J, Drings P, Baurecht W, Angermund R.

Radiother Oncol. 2014 Jul;112(1):23-9. doi: 10.1016/j.radonc.2014.06.005. Epub 2014 Aug 13.

PMID:
25129551
2.

[Use of erythropoiesis stimulating agents].

Lapierre A, Souquet PJ.

Rev Mal Respir. 2014 Feb;31(2):162-72. doi: 10.1016/j.rmr.2013.10.002. Epub 2013 Oct 28. Review. French.

PMID:
24602683
3.

Synchronization of administrations of chemotherapy and erythropoiesis-stimulating agents and frequency of associated healthcare visits.

Hill JW, Shreay S, McGarvey N, De AP, Hess GP, Corey-Lisle PK.

Support Care Cancer. 2013 Nov;21(11):2957-65. doi: 10.1007/s00520-013-1830-7. Epub 2013 Jun 12.

PMID:
23756616
4.

Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients.

Thomaidis T, Weinmann A, Sprinzl M, Kanzler S, Raedle J, Ebert M, Schimanski CC, Galle PR, Hoehler T, Moehler M; Upper-GI-Group of AIO (Arbeitsgemeinschaft Internistische Onkologie), Germany.

Int J Clin Oncol. 2014 Apr;19(2):288-96. doi: 10.1007/s10147-013-0544-7. Epub 2013 Mar 27.

PMID:
23532629
5.

Effects of exercise on fatigue, sleep, and performance: a randomized trial.

Coleman EA, Goodwin JA, Kennedy R, Coon SK, Richards K, Enderlin C, Stewart CB, McNatt P, Lockhart K, Anaissie EJ.

Oncol Nurs Forum. 2012 Sep;39(5):468-77. doi: 10.1188/12.ONF.468-477.

PMID:
22940511
6.

[Treatment of anaemia in medical oncology].

Kullmann T, Culine S.

Orv Hetil. 2012 Jun 24;153(25):973-7. doi: 10.1556/OH.2012.29371. Review. Hungarian.

PMID:
22714031
7.

Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation.

Fujisaka Y, Sugiyama T, Saito H, Nagase S, Kudoh S, Endo M, Sakai H, Ohashi Y, Saijo N.

Br J Cancer. 2011 Oct 25;105(9):1267-72. doi: 10.1038/bjc.2011.395. Epub 2011 Sep 29.

8.

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial.

Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.

Cancer. 2012 Feb 1;118(3):848-55. doi: 10.1002/cncr.26341. Epub 2011 Jul 12.

9.

Recombinant human erythropoietin β: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients.

Durmaz O, Demirkaya M, Sevinir B.

Pediatr Hematol Oncol. 2011 Sep;28(6):461-8. doi: 10.3109/08880018.2011.570857. Epub 2011 Jun 27.

PMID:
21707225
10.
11.

Effect of erythropoietin, 5-fluorouracil and SN-38 on the growth of DLD-1 cells.

Tankiewicz-Kwedlo A, Pawlak D, Domaniewski T, Buczko W.

Pharmacol Rep. 2010 Sep-Oct;62(5):926-37.

12.

Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study.

Macciò A, Madeddu C, Gramignano G, Mulas C, Sanna E, Mantovani G.

Oncologist. 2010;15(8):894-902. doi: 10.1634/theoncologist.2010-0020. Epub 2010 Jul 20.

13.

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial.

Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.

J Clin Oncol. 2010 May 1;28(13):2239-45. doi: 10.1200/JCO.2009.25.1835. Epub 2010 Apr 5.

14.

Effects of CERA (continuous erythropoietin receptor activator) in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemotherapy: results of a phase II study.

Gascon P, Pirker R, Del Mastro L, Durrwell L.

Ann Oncol. 2010 Oct;21(10):2029-39. doi: 10.1093/annonc/mdq073. Epub 2010 Mar 24.

15.

High serum levels of TNF-α and IL-6 predict the clinical outcome of treatment with human recombinant erythropoietin in anaemic cancer patients.

Pavese I, Satta F, Todi F, Di Palma M, Piergrossi P, Migliore A, Piselli P, Borghesi R, Mancino G, Brunetti E, Alimonti A.

Ann Oncol. 2010 Jul;21(7):1523-8. doi: 10.1093/annonc/mdp568. Epub 2009 Dec 23.

16.

Population-based analysis of the frequency of anemia and its management before and during chemotherapy in patients with malignant lymphoma.

Truong PT, Parhar T, Hart J, Alexander C, Wai ES.

Am J Clin Oncol. 2010 Oct;33(5):465-8. doi: 10.1097/COC.0b013e3181b4b147.

PMID:
19935386
17.

Therapeutic effects of epoetin zeta in the treatment of chemotherapy-induced anaemia.

Tzekova V, Mihaylov G, Elezovic I, Koytchev R; Epoetin Zeta Oncology Study Group.

Curr Med Res Opin. 2009 Jul;25(7):1689-97. doi: 10.1185/03007990903050876.

PMID:
19505200
18.

Ninth Biannual Report of the Cochrane Haematological Malignancies Group--focus on hematopoietic growth factors.

Skoetz N, Weingart O, Monsef I, Bauer K, Brillant C, Herbst C, Kluge S, Engert A; Cochrane Haematological Malignancies Group.

J Natl Cancer Inst. 2009 May 6;101(9):E1. doi: 10.1093/jnci/djp091. Epub 2009 Apr 28. Review. No abstract available.

19.

Effects of epoetin-alpha on quality of life of cancer patients with solid tumors receiving chemotherapy.

Christodoulou C, Dafni U, Aravantinos G, Koutras A, Samantas E, Karina M, Janinis J, Papakostas P, Skarlos D, Kalofonos HP, Fountzilas G.

Anticancer Res. 2009 Feb;29(2):693-702.

20.

Optimized pro-active management of anemia by Epoetin alpha in pre-operative chemotherapy for primary breast cancer.

Warm M, Kates R, Dick M, Thomas A, Mallmann P, Hoopmann M, Harbeck N.

Oncol Rep. 2009 Mar;21(3):777-85.

PMID:
19212639
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk